Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 6:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 114 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Eribulin mesylate Clear all
Terminated Phase 2 Interventional Results available

Trial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer

NCT01498588
View directory record Official record
Conditions
Breast Neoplasms, Breast Cancer, Breast Tumors, Cancer of the Breast, Neoplasms, Breast, Tumors, Breast
Interventions
Eribulin, Doxorubicin, Cyclophosphamide, Pegfilgrastim
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
4
States / cities
Atlanta, Georgia • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 2, 2016 · Synced Sep 5, 2026, 6:34 AM EDT
Completed Phase 2 Interventional Results available

Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma

NCT02097238
View directory record Official record
Conditions
Recurrent Osteosarcoma
Interventions
Eribulin Mesylate, Pharmacological Study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years to 49 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
116
States / cities
Birmingham, Alabama • Phoenix, Arizona • Downey, California + 76 more
Source: ClinicalTrials.gov public record
Updated May 18, 2020 · Synced Sep 5, 2026, 6:34 AM EDT
Completed Phase 1 Interventional

Eribulin Mesylate and Cisplatin in Treating Patients With Advanced Solid Tumors

NCT00415324
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
eribulin mesylate, cisplatin, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
4
States / cities
Duarte, California • Los Angeles, California • Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Sep 5, 2026, 6:34 AM EDT
Completed Phase 3 Interventional Results available

Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer

NCT02492711
View directory record Official record
Conditions
HER-2 Positive Breast Cancer, Metastatic Neoplasm
Interventions
Margetuximab, Trastuzumab, Physician's choice of chemotherapy.
Biological · Drug
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years and older
Enrollment
624 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
62
States / cities
Chandler, Arizona • Gilbert, Arizona • Goodyear, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2025 · Synced Sep 5, 2026, 6:34 AM EDT
Completed Phase 2 Interventional Results available

A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer

NCT01268150
View directory record Official record
Conditions
Locally Recurrent, Metastatic Breast Cancer ( HER2 Negative)
Interventions
Eribulin mesylate
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
17
States / cities
Miami, Florida • Augusta, Georgia • Macon, Georgia + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Sep 5, 2026, 6:34 AM EDT
Completed Phase 2 Interventional Results available

Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer

NCT01269346
View directory record Official record
Conditions
Breast Cancer
Interventions
Eribulin Mesylate
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
26
States / cities
Denver, Colorado • Davie, Florida • Jacksonville, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Sep 5, 2026, 6:34 AM EDT
Completed Phase 1 Interventional

Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors

NCT02014337
View directory record Official record
Conditions
Breast Cancer, Ovarian Epithelial Cancer Recurrent, Sarcoma, Non-small Cell Lung Cancer, Carcinoma, Transitional Cell, Prostate Cancer, Prostatic Neoplasms
Interventions
Mifepristone and Eribulin in combination
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
11
States / cities
Tucson, Arizona • Tampa, Florida • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2018 · Synced Sep 5, 2026, 6:34 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer

NCT01126749
View directory record Official record
Conditions
Bladder Cancer
Interventions
Gemcitabine, E7389, Cisplatin
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
14
States / cities
Birmingham, Alabama • Tucson, Arizona • Fort Myers, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2022 · Synced Sep 5, 2026, 6:34 AM EDT
Completed Phase 1 Interventional Results available

Study of E7389 Administered Once Every 3 Weeks In Patients With Advanced Solid Tumors

NCT00069277
View directory record Official record
Conditions
Cancer
Interventions
E7389
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
3
States / cities
Los Angeles, California • Santa Monica, California • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 10, 2012 · Synced Sep 5, 2026, 6:34 AM EDT
Terminated Phase 2 Interventional

Phase 2 Trial of AEZS-108 in Chemotherapy Refractory in Triple Negative Breast Cancer

NCT01698281
View directory record Official record
Conditions
Breast Cancer
Interventions
AEZS-108, SCCC, Dexamethasone
Drug
Lead sponsor
AEterna Zentaris
Industry
Eligibility
18 Years and older · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 21, 2018 · Synced Sep 5, 2026, 6:34 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

NCT05374512
View directory record Official record
Conditions
Breast Cancer
Interventions
Dato-DXd, Paclitaxel, Nab-paclitaxel, Carboplatin, Capecitabine, Eribulin mesylate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
644 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
27
States / cities
Duarte, California • Los Angeles, California • San Francisco, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Sep 5, 2026, 6:34 AM EDT
Completed Phase 2 Interventional Results available

Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer

NCT01104155
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
eribulin mesylate + erlotinib
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
50
States / cities
Bessemer, Alabama • Birmingham, Alabama • Beverly Hills, California + 47 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Sep 5, 2026, 6:34 AM EDT
Terminated Phase 1 Interventional

Evaluate Eribulin ORA in Subjects With Solid Tumors

NCT04013217
View directory record Official record
Conditions
Solid Tumor
Interventions
Eribulin ORA
Combination Product
Lead sponsor
Health Hope Pharma
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Apr 12, 2025 · Synced Sep 5, 2026, 6:34 AM EDT
Completed Phase 3 Interventional Results available

SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer

NCT03262935
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
(vic-)trastuzumab duocarmazine, Physician's choice
Drug
Lead sponsor
Byondis B.V.
Industry
Eligibility
18 Years and older · Female only
Enrollment
437 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
23
States / cities
Mobile, Alabama • Tucson, Arizona • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2023 · Synced Sep 5, 2026, 6:34 AM EDT
Completed Not applicable Interventional Results available

Compassionate Use of Eribulin for the Treatment of Advanced Breast Cancer Refractory to All Other Marketed Therapies

NCT01142661
View directory record Official record
Conditions
Breast Cancer
Interventions
Eribulin Mesylate
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
5
States / cities
La Verne, California • Nyack, New York • Raleigh, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2013 · Synced Sep 5, 2026, 6:34 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer

NCT05041101
View directory record Official record
Conditions
Breast Inflammatory Carcinoma, Recurrent Breast Inflammatory Carcinoma, Stage IV Breast Inflammatory Carcinoma
Interventions
Eribulin Mesylate, Grapiprant
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Sep 5, 2026, 6:34 AM EDT
Terminated Phase 1 Interventional

M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer

NCT03579472
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
Interventions
Bintrafusp Alfa, Eribulin Mesylate
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 30, 2022 · Synced Sep 5, 2026, 6:34 AM EDT
Not listed Phase 2 Interventional

Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients

NCT01372579
View directory record Official record
Conditions
Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Male Breast Cancer, Progesterone Receptor-negative Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Triple-negative Breast Cancer
Interventions
eribulin mesylate, carboplatin, biopsy
Drug · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 6, 2019 · Synced Sep 5, 2026, 6:34 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma

NCT01327885
View directory record Official record
Conditions
Soft Tissue Sarcoma
Interventions
Eribulin mesylate 1.4 mg/m^2 intravenous, Dacarbazine of 850 mg/m^2, or 1,000 mg/m^2, or 1,200 mg/m^2 IV
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
30
States / cities
Tucson, Arizona • Los Angeles, California • Orange, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Sep 5, 2026, 6:34 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

NCT05824975
View directory record Official record
Conditions
Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS), Platinum-resistant Ovarian Cancer (PROC), Hepatocellular Carcinoma (HCC), Colorectal Cancer (CRC), HER2 Negative Breast Cancer, Cutaneous Melanoma, Renal Cell Carcinoma (RCC)
Interventions
GI-102 subcutaneous (SC), GI-102, doxorubicin, paclitaxel, bevacizumab, eribulin, trastuzumab deruxtecan (T-DXd), pembrolizumab
Drug
Lead sponsor
GI Innovation, Inc.
Industry
Eligibility
18 Years and older
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
5
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2024 · Synced Sep 5, 2026, 6:34 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)

NCT02513472
View directory record Official record
Conditions
Breast Neoplasm
Interventions
Eribulin Mesylate, Pembrolizumab
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
22
States / cities
Duarte, California • Santa Barbara, California • Denver, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated May 4, 2022 · Synced Sep 5, 2026, 6:34 AM EDT
Completed Phase 3 Interventional Results available

The BEACON Study (Breast Cancer Outcomes With NKTR-102)

NCT01492101
View directory record Official record
Conditions
Locally Recurrent Breast Cancer, Metastatic Breast Cancer
Interventions
NKTR-102, Treatment of Physician's Choice (TPC)
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years and older · Female only
Enrollment
852 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
88
States / cities
Flagstaff, Arizona • Burbank, California • Los Angeles, California + 74 more
Source: ClinicalTrials.gov public record
Updated May 31, 2021 · Synced Sep 5, 2026, 6:34 AM EDT
Completed Phase 2 Interventional Results available

Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)

NCT03331250
View directory record Official record
Conditions
Angiosarcoma, Epithelioid Hemangioendothelioma
Interventions
Eribulin
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 5, 2026, 6:34 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

NCT03424005
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Capecitabine, Atezolizumab, Ipatasertib, SGN-LIV1A, Bevacizumab, Chemotherapy (Gemcitabine + Carboplatin or Eribulin), Selicrelumab, Tocilizumab, Nab-Paclitaxel, Sacituzumab Govitecan, Abemaciclib, Fulvestrant, Ribociclib (Dose #1), Inavolisib (Dose #1), Trastuzumab Deruxtecan, Ribociclib (Dose #2), Letrozole, Inavolisib (Dose #2), Empagliflozin, Palbociclib, Metformin, Atirmociclib, Giredestrant
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
20
States / cities
Duarte, California • La Jolla, California • Stanford, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 5, 2026, 6:34 AM EDT